The overall objective of this project is to understand how the unique substrate specificities of the mammalian microsomal cytochrome P450 enzymes arise. These enzymes participate in the metabolism of a wide range of drugs and environmental contaminants. Differences in P450 structure or expression can lead to inter-individual differences in drug metabolism that determine safe exposure limits for these compounds. Evolutionary divergence leads to functional differences between orthologous P450s that render extrapolation of animal studies to man imprecise. This underscores the importance of directly characterizing human P450s and of developing methods to predict drug metabolism. Mammalian P450s are membrane proteins, and this has limited the generation of crystals suitable for structural studies. Suitable modifications to the membrane binding domains of P450 2C5 reduced membrane association while promoting solubility and mono-dispersity. The modified P450 2C5 was crystallized leading to the determination of the first structure of a mammalian P450. The proposed studies will better characterize structural determinants of human drug metabolism by addressing three specific aims. (1) The approach taken to crystallize 2C5 will be extended to the human drug metabolizing P450s 2C9, 2D6 and 3A4. Additional modifications that may be necessary to produce soluble, active human P450s will be identified using chimeric proteins harboring alterations that allowed crystallization of 2C5. (2) The membrane topology of 2C5 will be better defined through the use of anti-peptide antibodies to identify portions of the microsomal membrane bound protein that are exposed. This information will be used as a design aid to address the first specific aim. (3) Models for the substrate specificity of human drug metabolizing enzymes will be generated based on the structure of 2C5. Hypotheses regarding determinants of substrate specificity will be tested by engineering 2C5 to mimic the activities of the human enzyme. These studies will increase our ability to predict human drug metabolism.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM031001-18
Application #
2904406
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1982-08-01
Project End
2003-07-31
Budget Start
1999-08-01
Budget End
2000-07-31
Support Year
18
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Jennings, Gareth K; Hsu, Mei-Hui; Shock, Lisa S et al. (2018) Noncovalent interactions dominate dynamic heme distortion in cytochrome P450 4B1. J Biol Chem 293:11433-11446
Hsu, Mei-Hui; Savas, Uzen; Johnson, Eric F (2018) The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5. Mol Pharmacol 93:14-24
Butler, Christopher R; Ogilvie, Kevin; Martinez-Alsina, Luis et al. (2017) Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality. J Med Chem 60:386-402
Hsu, Mei-Hui; Baer, Brian R; Rettie, Allan E et al. (2017) The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ?-Hydroxylation. J Biol Chem 292:5610-5621
Liu, Renhe; Lyu, Xiaoxuan; Batt, Sarah M et al. (2017) Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. Angew Chem Int Ed Engl 56:13011-13015
Brodney, Michael A; Beck, Elizabeth M; Butler, Christopher R et al. (2015) Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors. J Med Chem 58:3223-52
Wang, An; Stout, C David; Zhang, Qinghai et al. (2015) Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. J Biol Chem 290:5092-104
Johnson, Eric F; Connick, J Patrick; Reed, James R et al. (2014) Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges. Drug Metab Dispos 42:9-22
Johnson, Eric F; Stout, C David (2013) Structural diversity of eukaryotic membrane cytochrome p450s. J Biol Chem 288:17082-90
Reynald, R Leila; Sansen, Stefaan; Stout, C David et al. (2012) Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem 287:44581-91

Showing the most recent 10 out of 80 publications